Drugs / SX-682
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07814352 | Sep 2026 → Sep 2029 expected | malignant tumor of meninges | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06622005 | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04477343 | Nov 2020 → May 2026 overdue | pancreatic ductal adenocarcinoma | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04245397 | Jun 2020 → Mar 2028 expected | myelodysplastic syndrome | Syntrix Biosystems, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03161431 | Jun 2019 → Aug 2026 overdue | metastatic melanoma | Syntrix Biosystems, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07667400 | Oct 2026 → Oct 2036 expected | adenoid cystic carcinoma, castration-resistant prostate carcinoma, hypopharyngeal carcinoma, laryngeal carcinoma +5 | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07002320 | Apr 2025 → Oct 2029 expected | prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06149481 | Mar 2024 → Oct 2027 expected | colorectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04574583 | Nov 2020 → Feb 2023 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT04599140 | Oct 2020 → Jul 2026 overdue | colon adenocarcinoma, rectum adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07322341 | Oct 2026 → Nov 2030 expected | non-small cell lung carcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06228053 | Nov 2024 → Jun 2027 expected | prostate carcinoma | Syntrix Biosystems, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05604560 | Nov 2023 → Dec 2027 expected | pancreatic adenocarcinoma | Lei Zheng | Recruiting | No outcome recorded |
| Phase 2 | NCT05570825 | Apr 2023 → Jul 2027 expected | non-small cell lung carcinoma | University of Washington | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2024-05-25 | Syntrix Biosystems, Inc. | Results ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma syntrixbio.com ↗
Results support the clinical activity of SX-682 in metastatic melanoma ( Abstract ). |
| 2022-12-30 | Syntrix Biosystems, Inc. | Results New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models syntrixbio.com ↗
After 540 days, all but one of the 10 mice in a group with a highly virulent pancreatic cancer were still alive after being treated with the three-agent combination. |
| 2022-12-08 | Syntrix Biosystems, Inc. | Results First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes syntrixbio.com ↗
There was a dose-dependent increase in overall response rate (ORR) from 0% at 25 mg BID to 50% at 200 mg BID (response assessments per 2006 IWG MDS criteria). |
| 2021-08-08 | Syntrix Biosystems, Inc. | Results New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer syntrixbio.com ↗
The study concludes that the results support testing of RAS/ERK pathway inhibitors with SX-682 in NSCLC patients. |
| 2020-01-06 | Syntrix Biosystems, Inc. | Results Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies syntrixbio.com ↗
Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal immunosuppressive cell barriers in solid tumors to enhance checkpoint inhibition in non-small cell lung cancer (NSCLC) and natural killer (NK) cell-based immunotherapy in head and neck squamous cell carcinoma (HNSCC), respectively. |
| 2019-04-08 | Syntrix Biosystems, Inc. | Results Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors syntrixbio.com ↗
The researchers found that neutrophilic-MDSCs (PMN-MDSCs) were the most abundant myeloid cell within the tumors and caused the greatest suppression of immune-mediated tumor killing. |
| 2019-03-26 | Syntrix Biosystems, Inc. | Results New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer syntrixbio.com ↗
Findings from the study, published in the March 21 online issue of Cancer Cell , show that inhibition of CXCR2 by SX-682 increased sensitivity to ICB therapy. |
| 2017-03-30 | Syntrix Biosystems, Inc. | Results Study Published in Nature Provides Path for New Immunotherapy to Prostate Cancer Using SX-682 – Results Underpin Clinical Trial of SX-682 With Anti-PD1 and Anti-CTLA4 Combination syntrixbio.com ↗
However, the addition of SX-682 made previously “cold” ICB “hot”, with significant reduction in the average tumor mass. |
| 2016-04-07 | Syntrix Biosystems, Inc. | Regulatory Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor syntrixbio.com ↗
Syntrix today announced that it has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 trial of SX-682. |
All press releases naming this drug 13 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SX-682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03161431 ↗ |
| Action | Inhibit | “SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)” NCT03161431 ↗ |
| Modality | Small molecule | “SX-682 is an oral small molecule selective inhibitor” NCT03161431 ↗ |
| Route | Oral | “SX-682 is an oral small molecule” NCT03161431 ↗ |
| Target | CXCR1 | “selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1)” NCT03161431 ↗ |